0001341235-15-000001.txt : 20150129 0001341235-15-000001.hdr.sgml : 20150129 20150129144956 ACCESSION NUMBER: 0001341235-15-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20150129 DATE AS OF CHANGE: 20150129 EFFECTIVENESS DATE: 20150129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc. CENTRAL INDEX KEY: 0001341235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-233108 FILM NUMBER: 15558526 BUSINESS ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-761-4904 MAIL ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: Aldexa Therapeutics, Inc. DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Neuron Systems Inc DATE OF NAME CHANGE: 20051012 D 1 primary_doc.xml X0707 D LIVE 0001341235 Aldeyra Therapeutics, Inc. 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA MASSACHUSETTS 02421 781-761-4904 DELAWARE Aldexa Therapeutics, Inc. Neuron Systems Inc Corporation true Todd C. Brady 131 Hartwell Avenue Suite 320 Lexington MA MASSACHUSETTS 02421 Executive Officer Director Stephen Tulipano 131 Hartwell Avenue Suite 320 Lexington MA MASSACHUSETTS 02421 Executive Officer Scott L. Young 131 Hartwell Avenue Suite 320 Lexington MA MASSACHUSETTS 02421 Executive Officer C. Boyd Clarke 131 Hartwell Avenue Suite 320 Lexington MA MASSACHUSETTS 02421 Director Martin J. Joyce 131 Hartwell Avenue Suite 320 Lexington MA MASSACHUSETTS 02421 Director Gary Phillips 131 Hartwell Avenue Suite 320 Lexington MA MASSACHUSETTS 02421 Director Ben Bronstein 131 Hartwell Avenue Suite 320 Lexington MA MASSACHUSETTS 02421 Director Neal Walker 131 Hartwell Avenue Suite 320 Lexington MA MASSACHUSETTS 02421 Director Jesse I. Treu 131 Hartwell Avenue Suite 320 Lexington MA MASSACHUSETTS 02421 Director Biotechnology Decline to Disclose 06b false 2015-01-14 false true true false 0 18365820 7791560 10574260 The Total Offering Amount represents the shares of stock sold plus the exercise price of the warrants. The Total Amount Sold represents the shares of stock sold; the Total Remaining to be Sold represents the aggregate exercise price of the warrants. false 16 0 0 0 false Aldeyra Therapeutics, Inc. Todd C. Brady Todd C. Brady President and Chief Executive Officer 2015-01-29